Literature DB >> 22982663

EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.

Allison Ackerman1, Michael A Goldstein, Susumu Kobayashi, Daniel B Costa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22982663      PMCID： PMC3444741          DOI： 10.1097/JTO.0b013e3182635ab4

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  6 in total

1.  Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations.

Authors:  Yasushi Yatabe; William Pao; James R Jett
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

2.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

Review 3.  EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.

Authors:  Hiroyuki Yasuda; Susumu Kobayashi; Daniel B Costa
Journal:  Lancet Oncol       Date:  2011-07-19       Impact factor: 41.316

4.  Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.

Authors:  Jenn-Yu Wu; Chong-Jen Yu; Yeun-Chung Chang; Chih-Hsin Yang; Jin-Yuan Shih; Pan-Chyr Yang
Journal:  Clin Cancer Res       Date:  2011-04-29       Impact factor: 12.531

5.  Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities.

Authors:  Elizabeth M Gaughan; Daniel B Costa
Journal:  Ther Adv Med Oncol       Date:  2011-05       Impact factor: 8.168

6.  Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.

Authors:  Shang-Gin Wu; Yih-Leong Chang; Jou-Wei Lin; Chen-Tu Wu; Hsuan-Yu Chen; Meng-Feng Tsai; Yung-Chie Lee; Chong-Jen Yu; Jin-Yuan Shih
Journal:  PLoS One       Date:  2011-08-09       Impact factor: 3.240
  6 in total
  9 in total

1.  Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements.

Authors:  Daniel B Costa
Journal:  Transl Lung Cancer Res       Date:  2016-06

2.  Complete Response to Afatinib of an EGFR Exon 18 delE709_T710insD-Mutated Stage IV Lung Adenocarcinoma.

Authors:  Blandine Jelli; Olivier Taton; Nicky D'Haene; Myriam Remmelink; Zita Mekinda
Journal:  Eur J Case Rep Intern Med       Date:  2021-08-11

3.  Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report.

Authors:  Fei Xu; Meng-Ling Xia; Hui-Yun Pan; Jiong-Wei Pan; Yi-Hong Shen
Journal:  World J Clin Cases       Date:  2022-06-16       Impact factor: 1.534

4.  Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.

Authors:  Satoshi Watanabe; Yuji Minegishi; Hirohisa Yoshizawa; Makoto Maemondo; Akira Inoue; Shunichi Sugawara; Hiroshi Isobe; Masao Harada; Yoshiki Ishii; Akihiko Gemma; Koichi Hagiwara; Kunihiko Kobayashi
Journal:  J Thorac Oncol       Date:  2014-02       Impact factor: 15.609

5.  Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer.

Authors:  Jenn-Yu Wu; Jin-Yuan Shih
Journal:  Onco Targets Ther       Date:  2016-10-11       Impact factor: 4.147

6.  Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report.

Authors:  Ning An; Haoyi Wang; Hui Zhu; Weiwei Yan; Wang Jing; Li Kong; Yan Zhang; Jinming Yu
Journal:  Onco Targets Ther       Date:  2019-09-10       Impact factor: 4.147

7.  Analysis of Predictive Biomarkers in Patients With Lung Adenocarcinoma From Southern Brazil Reveals a Distinct Profile From Other Regions of the Country.

Authors:  Tiago F Andreis; Bruno S Correa; Fernanda S Vianna; Fernanda De-Paris; Marina Siebert; Sandra Leistner-Segal; Eriza C Hahn; Jane M Ulbrich; Luis F R Rivero; Francine H De Oliveira; Vinícius Lorandi; Patricia Ashton-Prolla; Gabriel S Macedo
Journal:  J Glob Oncol       Date:  2019-09

8.  A Lung Adenocarcinoma Patient With a Rare EGFR E709_T710delinsD Mutation Showed a Good Response to Afatinib Treatment: A Case Report and Literature Review.

Authors:  Yu Wei; Yueli Cui; Yao Guo; Lei Li; Liang Zeng
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

9.  The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive.

Authors:  Su Yu; Yang Zhang; Yunjian Pan; Chao Cheng; Yihua Sun; Haiquan Chen
Journal:  Onco Targets Ther       Date:  2017-09-12       Impact factor: 4.147
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.